LATAM Fabry Disease Market, by Therapy Type (Enzyme Replacement Therapy (Agalsidase Beta (Fabrazyme), Agalsidase Alfa (Replagal), Pegunigalsidase Alfa (PRX-102, Phase III)) Chaperon Therapy (Migalastat (Galafold Phase III)), Substrate Reduction Therapy (Lucerastat (Phase III), Venglustat (Phase III))), by Route of Administration (Oral, Parenteral), by Distribution Channel (Hospitals Pharmacies, Online pharmacies, Retail Pharmacies), and by Country (Brazil, Argentina, Mexico, Rest of Latin America) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Sep 2022

Code : CMI5249

Pages :245

Formats :

Excel and PDF

Industry : Pharmaceutical

LATAM Fabry Disease MarketSize and Trends

LATAM fabry disease market is estimated to be valued at US$ 81.330 Mn in 2022 and is expected to exhibit a CAGR of 6.7% over the forecast period (2022-2030)

Figure 1: LATAM Fabry Disease Market Share, (%), Analysis, By Therapy Type, 2022

Development of consensus document for the diagnosis of fabry disease by Brazilian Society of Nephrology, is expected to drive the market growth of the LATAM fabry disease market, over the forecast period.

Development of consensus documents for fabry disease by health care community is expected to drive the market growth of the LATAM fabry disease market, over the forecast period. For instance, according to data published in June, 2022 by Brazilian Journal of Nephrology, Committee for Rare Diseases - Brazilian Society of Nephrology, developed a consensus document to standardize recommendations related to kidney involvement in fabry disease in the areas of diagnosis, screening, and treatment of adult and pediatric patients. The development of the consensus statement aims to assists physicians and patients regarding the results of the treatment for fabry disease.

Increasing research and development for drug development by key players present in Latin America is expected to drive growth of the LATAM fabry disease market, over the forecast period.

Increasing research and development for drug development by key players present in Latin America is expected to drive growth of the LATAM fabry disease market, over the forecast period. For instance, on October 23, 2019, Amicus Therapeutics, a biotechnology company, successfully completed a Phase III clinical trial for fabry disease. The study was conducted to evaluate the long-term safety and efficacy of Migalastat Hydrochloride Monotherapy in patients with fabry disease. The study reported 0.00% mortality of the patients who participated in clinical trials and about 30.95% patients have been reported with adverse effects.

LATAM Fabry Disease Market - Impact of the Coronavirus (COVID-19) Pandemic

The COVID-19 pandemic is expected to hamper growth of the LATAM fabry disease market, owing to negative impact on supply chain during the COVID-19 pandemic. For instance, according to data published by United Nations Office on Drugs and Crime, there was impact of the actions implemented to control the spread of the COVID-19 on drug supply chain, in the destination markets. Many countries have reported an overall shortage of numerous types of drugs at the retail level. The COVID-19 restriction had limited the distribution of drugs in market, at retail level.

Increasing price of the drugs during COVID-19 pandemic might have a negative impact on growth of the fabry disease market in Latin America. For instance, according to data published by United Nations Office on Drugs and Crime, complete lockdown was implemented in many countries worldwide during COVID-19 pandemic which resulted into disturbance in the transport of drugs from one country to other, which has caused price increase of the drugs globally which is expected to hamper growth of the LATAM fabry disease market.